Literature DB >> 24145326

Transplantation: rituximab induction only for sensitized kidney recipients?

Christian Morath1, Caner Süsal.   

Abstract

In contrast to earlier studies that showed a beneficial influence of rituximab on HLA antibody production after kidney transplantation, a recent report by Ashimine et al. questions such an effect. That previous studies included presensitized patients who are more prone to antibody development, might explain this controversy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24145326     DOI： 10.1038/nrneph.2013.230

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.

Authors:  J Sellarés; D G de Freitas; M Mengel; J Reeve; G Einecke; B Sis; L G Hidalgo; K Famulski; A Matas; P F Halloran
Journal:  Am J Transplant       Date:  2011-11-14       Impact factor: 8.086

2.  An integrative approach for the transplantation of high-risk sensitized patients.

Authors:  Christian Morath; Jörg Beimler; Gerhard Opelz; Jörg Ovens; Sabine Scherer; Jan Schmidt; Bruno Schmied; Marie-Luise Gross; Vedat Schwenger; Martin Zeier; Caner Süsal
Journal:  Transplantation       Date:  2010-09-27       Impact factor: 4.939

3.  Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.

Authors:  C Wiebe; I W Gibson; T D Blydt-Hansen; M Karpinski; J Ho; L J Storsley; A Goldberg; P E Birk; D N Rush; P W Nickerson
Journal:  Am J Transplant       Date:  2012-03-19       Impact factor: 8.086

4.  A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up.

Authors:  Gunnar Tydén; Henrik Ekberg; Gunnar Tufveson; Lars Mjörnstedt
Journal:  Transplantation       Date:  2012-08-15       Impact factor: 4.939

5.  Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.

Authors:  N Kohei; T Hirai; K Omoto; H Ishida; K Tanabe
Journal:  Am J Transplant       Date:  2011-11-04       Impact factor: 8.086

Review 6.  B-cell immunotherapeutics: emerging roles in solid organ transplantation.

Authors:  Stanley C Jordan; Joseph Kahwaji; Mieko Toyoda; Ashley Vo
Journal:  Curr Opin Organ Transplant       Date:  2011-08       Impact factor: 2.640

Review 7.  Kidney transplantation across HLA and ABO antibody barriers.

Authors:  Luis E Becker; Caner Süsal; Christian Morath
Journal:  Curr Opin Organ Transplant       Date:  2013-08       Impact factor: 2.640

8.  A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.

Authors:  M D Stegall; J Gloor; J L Winters; S B Moore; S Degoey
Journal:  Am J Transplant       Date:  2006-02       Impact factor: 8.086

9.  Rituximab and intravenous immune globulin for desensitization during renal transplantation.

Authors:  Ashley A Vo; Marina Lukovsky; Mieko Toyoda; Jennifer Wang; Nancy L Reinsmoen; Chih-Hung Lai; Alice Peng; Rafael Villicana; Stanley C Jordan
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245

10.  Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.

Authors:  Satoshi Ashimine; Yoshihiko Watarai; Takayuki Yamamoto; Takahisa Hiramitsu; Makoto Tsujita; Koji Nanmoku; Norihiko Goto; Asami Takeda; Akio Katayama; Kazuharu Uchida; Takaaki Kobayashi
Journal:  Kidney Int       Date:  2013-08-14       Impact factor: 10.612
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.